Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, shared a post on X, about a recent paper by Che Hsuan David Wua et al. published in Radiotherapy and Oncology.

“The largest randomized phase III trial evaluating lung SBRT publishes a secondary analysis of 30 patients with ultra central tumors.”

“Toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer: A secondary analysis of the LUSTRE randomized trial”

Authors: Che Hsuan David Wua, Marcin Wierzbickib, Sameer Parpia, Timothy Whelank, Anand Swaminath et al.

Drew Moghanaki: The largest randomized phase III trial evaluating lung SBRT

More posts featuring Drew Moghanaki.

Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university.

He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).